Loading...
•
Sep 30, 2025
Zynex Q3 2025 Earnings Report
Zynex reported a significant year-over-year revenue decline and a substantial net loss in Q3 2025, impacted by Tricare payment suspension and impairment charges.
Key Takeaways
Zynex experienced a sharp downturn in revenue and earnings during Q3 2025 due to reimbursement issues, workforce reductions, and a large impairment charge. The company reported a net loss of $42.9 million and negative operating cash flow.
Revenue fell to $13.4 million, significantly down from $50.0 million a year ago.
Net loss was $42.9 million, impacted by a $30.7 million impairment charge.
Adjusted EBITDA came in at a loss of $12.3 million.
Cash and cash equivalents declined to $13.3 million as of September 30, 2025.
Revenue by Segment
Forward Guidance
The company is evaluating strategic alternatives and restructuring options due to ongoing liquidity challenges.
Positive Outlook
- Engaged Province LLC to explore strategic alternatives.
- Formed a Special Committee to guide strategic direction.
- Seeing progress on strategic turnaround plans.
- Reducing sales and administrative costs.
- Committed to rebuilding for future growth.
Challenges Ahead
- Entered grace period for $1.5M interest payment on convertible notes.
- Revenue impacted by Tricare payment suspension and payer delays.
- Significant impairment charge of $30.7 million.
- Net loss of $42.9 million in Q3 2025.
- Cash burn continues with negative operating cash flow.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...